NASDAQ:NRSN NeuroSense Therapeutics (NRSN) Stock Price, News & Analysis $6.35 -0.37 (-5.51%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$6.36 +0.01 (+0.08%) As of 09/18/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About NeuroSense Therapeutics Stock (NASDAQ:NRSN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get NRSN alerts:Sign Up Key Stats Today's Range$6.35▼$6.9950-Day Range$6.35▼$14.6052-Week Range$5.00▼$26.64Volume7,325 shsAverage Volume24,634 shsMarket Capitalization$12.07 millionP/E RatioN/ADividend YieldN/APrice Target$170.00Consensus RatingModerate Buy Company Overview NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. The company is headquartered in Israel and conducts research aimed at addressing biological mechanisms associated with diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurological disorders. NeuroSense’s leading investigational product is PrimeC, an oral, fixed-dose combination of ciprofloxacin and celecoxib. The therapy is designed to target multiple disease-related pathways, including neuroinflammation and the regulation of RNA processing, and has been evaluated in clinical studies involving patients with ALS. PrimeC has received regulatory designations intended to support its development for ALS, although it remains an investigational product and is not approved for commercial use. The company was founded in 2017 and is led by Chief Executive Officer Alon Ben-Noon. NeuroSense’s development strategy centers on combination therapies and proprietary formulations intended to address the complex, multi-factorial nature of neurodegenerative diseases.AI Generated. May Contain Errors. Read More NeuroSense Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreNRSN MarketRank™: NeuroSense Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 535th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingNeuroSense Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialNeuroSense Therapeutics has a consensus price target of $170.00, representing about 2,577.2% upside from its current price of $6.35.Amount of Analyst CoverageNeuroSense Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about NeuroSense Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for NeuroSense Therapeutics are expected to decrease in the coming year, from ($7.60) to ($13.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NeuroSense Therapeutics is -11.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NeuroSense Therapeutics is -11.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about NeuroSense Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.71% of the float of NeuroSense Therapeutics has been sold short.Short Interest Ratio / Days to CoverNeuroSense Therapeutics has a short interest ratio ("days to cover") of 1.46, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NeuroSense Therapeutics has recently decreased by 4.09%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeuroSense Therapeutics does not currently pay a dividend.Dividend GrowthNeuroSense Therapeutics does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A News SentimentNeuroSense Therapeutics has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for NeuroSense Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for NRSN on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows2 people have added NeuroSense Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, NeuroSense Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders27.40% of the stock of NeuroSense Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions1.04% of the stock of NeuroSense Therapeutics is held by institutions.Read more about NeuroSense Therapeutics' insider trading history. Receive NRSN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuroSense Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NRSN Stock News HeadlinesNeuroSense to Present at H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 10, 2026 | finance.yahoo.comHC Wainwright & Co. initiates coverage of NeuroSense Therapeutics (NRSN) with a buy ratingSeptember 4, 2026 | msn.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.September 19 at 1:00 AM | Stansberry Research (Ad)NeuroSense Unveils Accelerated, Capital-Efficient PrimeC Development Strategy In ALSSeptember 3, 2026 | rttnews.comNeuroSense Rewrites the Standard ALS Playbook With a Faster, Leaner Path to Potential ApprovalAugust 31, 2026 | markets.businessinsider.comNeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALSAugust 31, 2026 | prnewswire.comNeurosense Therapeutics (NRSN) Stock Forecast & Price TargetAugust 13, 2026 | investing.comNeurosense Therapeutics Stock Price HistoryAugust 13, 2026 | investing.comSee More Headlines NRSN Stock Analysis - Frequently Asked Questions How have NRSN shares performed this year? NeuroSense Therapeutics' stock was trading at $15.38 at the beginning of the year. Since then, NRSN stock has decreased by 58.7% and is now trading at $6.35. How were NeuroSense Therapeutics' earnings last quarter? NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) posted its quarterly earnings data on Monday, April, 7th. The company reported ($1.20) earnings per share for the quarter, topping analysts' consensus estimates of ($2.40) by $1.20. When did NeuroSense Therapeutics' stock split? NeuroSense Therapeutics shares reverse split on the morning of Monday, September 14th 2026.A 1-20 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, September 13th 2026. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did NeuroSense Therapeutics IPO? NeuroSense Therapeutics (NRSN) raised $13 million in an IPO on Wednesday, December 8th 2021. The company issued 2,000,000 shares at a price of $6.00-$7.00 per share. Who are NeuroSense Therapeutics' major shareholders? Top institutional investors of NeuroSense Therapeutics include Yorkville Advisors Global LP (0.21%). Insiders that own company stock include Alon Ben-Noon and Or Eisenberg. View institutional ownership trends. How do I buy shares of NeuroSense Therapeutics? Shares of NRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NeuroSense Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that NeuroSense Therapeutics investors own include Predictive Oncology (POAI), Ford Motor (F), Bank of America (BAC), JPMorgan Chase & Co. (JPM), Wells Fargo & Company (WFC), Abbott Laboratories (ABT) and Energy Select Sector SPDR Fund (XLE). Company Calendar Last Earnings4/07/2025Today9/19/2026Next Earnings (Estimated)12/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (8m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 NRSN's financial health is in the Red zone, according to TradeSmith. NRSN has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:NRSN CIK1875091 Webwww.neurosense-tx.com Phone972-9799-6183FaxN/AEmployees16Year FoundedN/APrice Target and Rating Average Price Target for NeuroSense Therapeutics$170.00 High Price Target$280.00 Low Price Target$60.00 Potential Upside/Downside+2,577.2%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.31 Quick Ratio0.31 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.96) per share Price / Book-6.61Miscellaneous Outstanding Shares1,900,000Free Float1,377,000Market Cap$12.07 million OptionableNot Optionable Beta1.60 The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:NRSN) was last updated on 9/19/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroSense Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroSense Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
